Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease.

ABSTRACT:

Background

Radium-223 chloride ((223)Ra; Alpharadin) is an alpha-emitting radioisotope that targets areas of osteoblastic metastasis and is excreted by the small intestine. When compared with beta-emitters (eg, strontium-89, samarium-153), (223)Ra delivers a high quantity of energy per track length with short tissue penetration.

Objective

This review describes the mechanism, radiobiology, and preclinical development of (223)Ra and discusses the clinical data currently available regarding its safety and efficacy profile.

Methods

Data from clinical trials including abstracts were collected and reviewed using the PubMed Database, as well as the American Society of Clinical Oncology abstract database.

Conclusion

Current bone-targeted therapies fall into two main ca

SUBMITTER: Harrison MR 

PROVIDER: S-EPMC3544343 | biostudies-literature | 2013

REPOSITORIES: biostudies-literature